CARDIFF ONCOLOGY, INC. Payments to Acquire Available-for-sale Securities
CARDIFF ONCOLOGY, INC. (CRDF) reported Payments to Acquire Available-for-sale Securities of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2020-02-27
- CARDIFF ONCOLOGY, INC. payments to acquire available-for-sale securities for the quarter ending 2019-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. payments to acquire available-for-sale securities for the quarter ending 2019-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. payments to acquire available-for-sale securities for the quarter ending 2018-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. payments to acquire available-for-sale securities for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- CARDIFF ONCOLOGY, INC. payments to acquire available-for-sale securities for fiscal 2018 was $31.50K, a 99.64% decline from fiscal 2017.
- CARDIFF ONCOLOGY, INC. payments to acquire available-for-sale securities for fiscal 2017 was $8.80M, a 76.68% decline from fiscal 2016.
- CARDIFF ONCOLOGY, INC. payments to acquire available-for-sale securities for fiscal 2016 was $37.76M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $31.50K derived: sum of 3 quarters · filed 2020-02-27 | $31.50K 10-K · filed 2020-02-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $31.50K derived: sum of 2 quarters · filed 2019-11-07 | $31.50K 10-Q · filed 2019-11-07 | $31.50K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $31.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $31.50K 10-Q · filed 2019-08-08 | $31.50K derived: sum of 3 quarters · filed 2019-08-08 | $31.50K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | $0.00 derived: sum of 2 quarters · filed 2019-03-06 | $0.00 derived: sum of 3 quarters · filed 2019-03-06 | $0.00 derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $0.00 derived: sum of 2 quarters · filed 2019-03-06 | $0.00 derived: sum of 3 quarters · filed 2019-03-06 | $8.80M 10-K · filed 2019-03-06 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $8.80M 10-Q · filed 2018-11-07 | $22.11M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $8.80M 10-Q · filed 2018-08-03 | $22.11M derived: sum of 3 quarters · filed 2018-08-03 | $18.61M derived: sum of 4 quarters · filed 2018-08-03 |
| 2017-03-31 | $8.80M 10-Q · filed 2018-05-08 | $22.11M derived: sum of 2 quarters · filed 2018-05-08 | $18.61M derived: sum of 3 quarters · filed 2018-05-08 | $46.56M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $13.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $9.81M derived: sum of 2 quarters · filed 2018-02-26 | $37.76M derived: sum of 3 quarters · filed 2018-02-26 | $37.76M 10-K · filed 2018-02-26 |
| 2016-09-30 | -$3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $24.45M derived: sum of 2 quarters · filed 2017-11-09 | $24.45M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $27.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $27.95M 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 | |||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-04 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |